Equities research analysts expect Aduro BioTech Inc (NASDAQ:ADRO) to report earnings of ($0.36) per share for the current quarter, according to Zacks. Four analysts have made estimates for Aduro BioTech’s earnings, with the lowest EPS estimate coming in at ($0.46) and the highest estimate coming in at ($0.30). Aduro BioTech posted earnings per share of ($0.44) during the same quarter last year, which indicates a positive year-over-year growth rate of 18.2%. The business is expected to issue its next quarterly earnings results on Wednesday, March 7th.
On average, analysts expect that Aduro BioTech will report full-year earnings of ($1.28) per share for the current year, with EPS estimates ranging from ($1.39) to ($1.22). For the next financial year, analysts expect that the company will report earnings of ($1.28) per share, with EPS estimates ranging from ($1.66) to ($0.78). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Aduro BioTech.
Aduro BioTech (NASDAQ:ADRO) last issued its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03). The firm had revenue of $3.79 million for the quarter, compared to the consensus estimate of $4.04 million. Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. Aduro BioTech’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.54) earnings per share.
Several brokerages have weighed in on ADRO. HC Wainwright set a $10.00 price objective on shares of Aduro BioTech and gave the stock a “buy” rating in a research note on Tuesday. BidaskClub cut shares of Aduro BioTech from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 3rd. Canaccord Genuity set a $30.00 price objective on shares of Aduro BioTech and gave the stock a “buy” rating in a research note on Thursday, December 14th. Oppenheimer decreased their price objective on shares of Aduro BioTech from $15.00 to $13.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 13th. Finally, William Blair reaffirmed an “outperform” rating on shares of Aduro BioTech in a research note on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $17.71.
In other news, insider Stephen T. Isaacs sold 20,200 shares of the stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $7.98, for a total transaction of $161,196.00. Following the sale, the insider now directly owns 190,321 shares of the company’s stock, valued at $1,518,761.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Dirk G. Brockstedt sold 4,123 shares of the stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $8.04, for a total transaction of $33,148.92. Following the sale, the executive vice president now directly owns 77,841 shares in the company, valued at $625,841.64. The disclosure for this sale can be found here. Insiders have sold 267,714 shares of company stock worth $2,251,452 over the last three months. 6.60% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ADRO. Russell Investments Group Ltd. acquired a new position in Aduro BioTech in the second quarter valued at approximately $408,000. Schwab Charles Investment Management Inc. lifted its holdings in Aduro BioTech by 13.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 165,338 shares of the biotechnology company’s stock valued at $1,885,000 after buying an additional 20,226 shares during the period. Rhumbline Advisers lifted its holdings in Aduro BioTech by 13.7% in the second quarter. Rhumbline Advisers now owns 44,889 shares of the biotechnology company’s stock valued at $512,000 after buying an additional 5,410 shares during the period. Legal & General Group Plc lifted its holdings in Aduro BioTech by 11.2% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 1,043 shares during the period. Finally, Swiss National Bank lifted its holdings in Aduro BioTech by 30.6% in the second quarter. Swiss National Bank now owns 50,300 shares of the biotechnology company’s stock valued at $573,000 after buying an additional 11,800 shares during the period. 45.19% of the stock is currently owned by institutional investors and hedge funds.
Shares of Aduro BioTech (NASDAQ ADRO) opened at $6.90 on Friday. The firm has a market cap of $533.40 and a PE ratio of -5.07. Aduro BioTech has a 52 week low of $6.01 and a 52 week high of $14.05.
COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Anticipate Aduro BioTech Inc (ADRO) to Post -$0.36 EPS” was first reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.truebluetribune.com/2018/01/19/zacks-brokerages-anticipate-aduro-biotech-inc-adro-to-post-0-36-eps.html.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.